Given the high burden of fungal co-infection in patients admitted to ICU and improved outcomes with prompt anti-fungal treatment, it is of vital importance that the doses of anti-fungal are optimum to improve the dismal outcome of influenza/Covid-19 Associated Pulmonary Aspergillosis. Due to the reported difficulties in dosing appropriately in ECMO patients, a prospective observational study is required to accurately evaluate the pharmacokinetics of voriconazole in patients supported on ECMO. This is to ensure that the dose of voriconazole is optimised to improve efficacy and reduce toxicity.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Plasma levels of voriconazole administered to critically ill adult patients with suspected fungal disease, receiving ECMO support.
Timeframe: 14 days
Plasma levels of voriconazole administered to critically ill adult patients with suspected fungal disease, receiving ECMO support.
Timeframe: 14 days
Plasma levels of voriconazole administered to critically ill adult patients with suspected fungal disease, receiving ECMO support.
Timeframe: 14 days
Plasma levels of voriconazole administered to critically ill adult patients with suspected fungal disease, receiving ECMO support.
Timeframe: 14 days
Plasma levels of voriconazole administered to critically ill adult patients with suspected fungal disease, receiving ECMO support.
Timeframe: 14 days